This meta- analysis shows that oral tibolone treatment significantly lowers circulating Lp(a ) levels in postmenopausal women .
INTRODUCTION Circulating lipoprotein ( a ) ( Lp(a ) ) is a recognized risk factor for cardiovascular disease ( CVD ) .
Tibolone , a synthetic steroid , may lower Lp(a ) levels ; however , evidence of the effects of tibolone on Lp(a ) still remain to be defined .
Therefore , we investigated the effects of tibolone treatment on circulating Lp(a ) levels in postmenopausal women .
Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist.
MGL-3196 is an oral , liver-targeted selective agonist for the thyroid hormone receptor-β ( THR-β ) that is being developed for the treatment of dyslipidemia . The safety profile and tolerability of THR-β agonist MGL-3196 was assessed in first-in humans studies , including a single ascending dose study ( NCT01367873 ) in which MGL-3196 appeared safe at all doses tested . A two-week multiple dose study was conducted at doses of 5 , 20 , 50 , 80 , 100 , and 200 mg per day in healthy subjects with mildly elevated low density lipoprotein ( LDL ) cholesterol ( > 110 mg/dL ) ( NCT01519531 ) . MGL-3196 was well-tolerated at all doses with no dose-related adverse events or liver enzyme , ECG or vital-sign changes . At the highest dose , there was a reversible reduction of ∼20 % in the level of pro-hormone , free thyroxine ( free T4 ) that was significantly different from placebo ( p < 0.0001 ) that may be explained by increased hepatic metabolism of T4 . There was no change in thyrotropin ( TSH ) or triiodothyronine ( free T3 ) or other evidence of central thyroid axis dysfunction at any dose . Doses ranging from 50 to 200 mg demonstrated highly statistically significant reductions relative to placebo of up to : 30 % for LDL cholesterol ( range , p = 0.05-<0.0001 ) ; 28 % for non- high density lipoprotein ( HDL ) cholesterol ( range , p = 0.027 - 0.0001 ) ; 24 % for Apolipoprotein B ( range , p = 0.008 - 0.0004 ) , and statistical trends of up to 60 % reduction in triglycerides ( TG ) ( range , p = 0.13 - 0.016 ) . The near maximal lipid effects were observed at a dose of 80 mg daily . In summary , in a two-week study in healthy volunteers with mild LDL cholesterol elevation , MGL-3196 appeared safe , was well-tolerated and showed a beneficial effect on lipid parameters
This meta- analysis shows that oral tibolone treatment significantly lowers circulating Lp(a ) levels in postmenopausal women .
INTRODUCTION Circulating lipoprotein ( a ) ( Lp(a ) ) is a recognized risk factor for cardiovascular disease ( CVD ) .
Tibolone , a synthetic steroid , may lower Lp(a ) levels ; however , evidence of the effects of tibolone on Lp(a ) still remain to be defined .
Therefore , we investigated the effects of tibolone treatment on circulating Lp(a ) levels in postmenopausal women .